Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock in a transaction on Friday, August 7th. The shares were sold at an average price of $7.60, for a total value of $38,000.00. Following the sale, the chief technology officer directly owned 182,171 shares of the company’s stock, valued at $1,384,499.60. This represents a 2.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total value of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.10, for a total value of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Stock Performance

Shares of SOPH opened at $7.61 on Wednesday. SOPHiA GENETICS SA has a 12-month low of $2.97 and a 12-month high of $7.88. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a market cap of $638.40 million, a PE ratio of -6.62 and a beta of 0.96. The stock has a 50-day moving average price of $5.73 and a 200-day moving average price of $5.18.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, equities analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Large investors have recently added to or reduced their stakes in the business. Sei Investments Co. bought a new stake in SOPHiA GENETICS in the first quarter worth $1,772,000. 1492 Capital Management LLC bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $973,000. Royce & Associates LP bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at about $2,009,000. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS in the first quarter worth about $2,157,000. Finally, Royal Bank of Canada increased its holdings in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after buying an additional 18,781 shares during the period. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target from $8 to $9 and HC Wainwright increased its target from $12 to $14; both firms maintained Buy ratings. The consensus target is approximately $10, suggesting potential upside from recent levels. SOPHiA GENETICS insider trading and analyst coverage
• Positive Sentiment: SOPHiA GENETICS reached a new one-year high, reflecting strong momentum after shares advanced substantially from their 52-week low of roughly $3. SOPHiA GENETICS reaches new one-year high
• Neutral Sentiment: Short interest was reported at zero shares, indicating no measurable short-selling pressure, although the reported comparison contained an invalid percentage change. The Q2 2026 earnings-call transcript was also released, but no additional quantified catalyst was provided in the available report. SOPHiA GENETICS Q2 2026 earnings call transcript
• Negative Sentiment: Chairman Jurgi Camblong sold a combined 28,500 shares for approximately $209,285, while CTO Abhimanyu Verma sold 5,000 shares for $38,000. Both transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their negative signaling, and both executives retained substantial positions. SOPHiA GENETICS insider sales
• Negative Sentiment: The latest quarter showed an adjusted loss of $0.26 per share versus the $0.21 consensus estimate, despite revenue of $23.31 million exceeding expectations. SOPHiA GENETICS remains unprofitable, with analysts forecasting a full-year loss of $0.77 per share.

Analyst Upgrades and Downgrades

SOPH has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright raised their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research upped their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.